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Abstract
This study was to investigate the role of complementary and alternative medicine in the prevention and treatment of benign prostatic hyperplasia.
For this purpose, a randomized, double-blind, placebo-controlled trial was performed over 12 months on 47 benign prostatic hyperplasia  patients 
with average age of 53.3 years and international prostate symptom score over 8. Subjects received either sweet potato starch (group A, placebo,
320 mg/day), pumpkin seed oil (group B, 320 mg/day), saw palmetto oil (group C, 320 mg/day) or pumpkin seed oil plus saw palmetto oil (group
D, each 320 mg/day). International prostate symptom score, quality of life, serum prostate specific antigen, prostate volume and maximal urinary
flow rate were measured. In groups B, C and D, the international prostate symptom score were reduced by 3 months. Quality of life score was 
improved after 6 months in group D, while those of groups B and C were improved after 3 months, compared to the baseline value. Serum prostate
specific antigen was reduced only in group D after 3 months, but no difference was observed in prostate volume in all treatment groups. Maximal
urinary flow rate were gradually improved in groups B and C, with statistical significance after 6 months in group B and after 12 months in group
C. None of the parameters were significantly improved by combined treatment with pumpkin seed oil and saw palmetto oil. From these results,
it is suggested that administrations of pumpkin seed oil and saw palmetto oil are clinically safe and may be effective as complementary and alternative
medicine treatments for benign prostatic hyperplasia.
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Introduction10)
Benign prostatic hyperplasia (BPH) is a pathological symptom 
frequently found in the elderly population. Treatment options for 
men with symptomatic BPH include active monitoring, 
phytochemical treatment, medical therapy with α-blockers or 5-α
-reductase inhibitors, and surgery (Barry et al., 1997; Watson 
et al., 2004). The use of complementary and alternative medicine 
(CAM) for the treatment of BPH patients has a long history, 
especially in European countries (Ortiz, 1998; Pathak et al., 
2003). Nevertheless, there is still a considerable degree of 
skepticism from the urologic community about the efficiency and 
safety of these CAM products. This is mainly due to the lack 
of an established mechanism of action for CAM (Melo et al., 
2002; Wilt et al., 1999) materials. The CAM used in this trial 
was pumpkin seed oil, saw palmetto oil and a combination of 
pumpkin seed oil and saw palmetto oil (Ernst, 2002; Hirsch, 
2000). For these materials, the mechanisms of action may include 
alteration of cholesterol metabolism, anti-androgenic activity 
(including 5-α-reductase inhibitor activity), anti-inflammatory 
effects, and a decrease in available sex hormone binding globulin 
(Cristoni  et al., 2000). Although the mechanisms of action of 
these materials have been investigated in many in vitro and 
indirect  in vivo studies, they have yet to be clearly defined 
(Shoskes, 2002; Wilt et al., 2000). Nevertheless, many BPH 
patients are currently taking these CAM materials everyday 
without apparent adverse effects (Vickers, 2000). Yet, long-term 
treatment of BPH patients with CAM is necessary in order to 
assess the occurrence of side effects. Therefore, the objective 
of this study was to carry out a long-term study to determine 
the effectiveness and the potential side effects of pumpkin seed 
oil and/or saw palmetto oil in the treatment of Korean men with 
symptomatic BPH.
Materials and Methods
Study design
BPH patients with an international prostate symptom score 
(IPSS) of 8 or more participated in a randomized, double-blind, 
placebo-controlled trial of pumpkin seed oil and saw palmetto 
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Table1. General characteristics of patients  (n=47)
Group A (n=7) B (n=16) C (n=13) D (n=11)
Age (year) 53.1 ± 4.2
1)a 48.3 ± 0.8
b 52.0 ± 1.8
a 59.6 ± 1.3
c
Height (cm) 168.9 ± 2.1 170.1 ± 1,0 169.5 ± 1.4 169.8 ± 1.1
Weight (kg) 69.0 ± 2.4 69.7 ± 2.0 70.8 ± 1.5 68.7 ± 2.3
BMI (kg/m
2) 24.2 ± 1.0 24.1 ± 0.6 24.7 ± 0.5 23.8 ± 0.7
1) Mean ± SE
Different superscripts within the same row are significantly different at α=0.05 by 
Tukey’s  studentized  range  test. 
BMI:  Body  mass  index  (body  weight / height
2 =k g / m
2)
Table 2. International prostate symptom scores
Group Baseline 3 Months 6 Months 9 Months 12 Months
A (n=7) 15.4 ± 2.8
1) 13.8 ± 2.6
(-10.4%)
11.0 ± 1.9
(-28.6%)
10.0 ± 1.8
(-35.1%)
 9.4 ± 1.8
(-39.0%)
B (n=16) 20.7 ± 2.3
a 13.7 ± 2.2
b
(-33.8%)
12.4 ± 1.6
b
(-40.1%)
 8.0 ± 1.5
b
(-61.4%)
 8.7 ± 1.5
b
(-58.0%)
C (n=13) 18.3 ± 2.0
a 13.7 ± 1.9
b
(-25.1%)
 9.6 ± 1.4
b
(-47.5%)
 7.5 ± 1.3
b
(-59.0%)
 9.1 ± 1.4
b
(-50.3%)
D (n=11) 19.0 ± 2.6
a 12.7 ± 2.5
b
(-33.2%)
 8.3 ± 1.8
bc
(-56.3%)
 7.1 ± 1.7
c
(-62.6%)
 4.7 ± 1.7
c
(-75.3%)
1) Mean ± SE  (adjusted  for  age)
Different superscripts within the same row are significantly different at α=0.05 by 
Tukey’s  range  test  with  age  adjusted.
oil for a 12-month period. Volunteers were requested to sign 
the documents of clinical examinations agreement after careful 
review of the instructions. Clinical examinations were conducted 
for 18 months at Chung-Ang University Medical Center, 
Department of Urology. 
By baseline checkup of general health, patients with any major 
diseases except BPH or patients who had BPH related treatment 
such as 5-α-reductase inhibitor, α-receptor blocker, urogenital 
surgery or any other alternative therapy for BPH were excluded. 
Any other medication or surgery related to BPH was not allowed 
during the trial.
Sixty-two patients were distributed into 4 separate groups 
according to their time sequence of participation; group A 
(placebo, control, sweet potato starch, 320 mg/day), group B 
(pumpkin seed oil, 320 mg/day), group C (saw palmetto oil, 320 
mg/day) and group D (the combination of pumpkin seed oil, 320 
mg/day and saw palmetto oil, 320 mg/day). Sweet potato starch 
(Bum-Ah, Seoul, Korea), standardized pumpkin seed oil and saw 
palmetto oil (RIA International, New Jersey, USA) were prepared 
in hard capsules. Patients took 2 capsules per day in the morning 
and the evening after a meal, over a 12-month period. After the 
baseline assessment of general health, each participant visited 
the hospital every 3 months to measure BPH parameters such 
as IPSS, quality of Life score (QoL), serum prostate specific 
antigen (PSA), prostate volume (PV) and maximal urinary flow 
rate (MFR). Fifteen patients (24%) were dropped during the trial 
due to aggravation of symptoms (n=13), movement (n=2) and 
initiation of BPH medication (n=1). 
Finally, 47 patients were completely participated in our study. 
They have been checked on overall functioning, difficulties with 
intervention adherence and adverse symptoms weekly by phone, 
and visited hospital every 3 months. 
Measurements
IPSS and QoL were assessed using standard questionnaire 
forms (2003 American Urology Association Guideline on the 
Management of BPH: Diagnosis and Treatment Recommenda-
tions) (Zhang et al., 2008). The questionnaire for IPSS is 
composed with seven questions and each measured on a 5 point 
scale. For the assessment, the patients responded on a scale of 
0 (delighted) to 6 (terrible) to the question, “If you were to spend 
the rest of your life with your urinary condition just the way 
it is now, how would you feel about this?” The serum PSA was 
measured using an electrochemiluminescence method (Cho et al., 
2005) (Elecsys systems modular E-170, Roche diagnostics 
GmbH, Germany). PV was measured using transrectal ultrasono-
graphy (Cho et al., 2005) (Voluson 730 proV GE Healthcare, 
Austria), and MFR was done using an uroflowmeter (Willetts 
et al., 2003) (Medtronic Urodyn 1000, High Med, Denmark). 
PV and MFR measurements started after 6 months because the 
urologists advised that there would not be a significant change 
over a short period such as the first 3 months of treatment. All 
patients were measured for body weight, height and body mass 
index (BMI) (Fanics Co. Ltd, HM-170, Korea) at the beginning 
of the experiment. 
Statistical analysis 
The differences among groups and experimental periods of 
each group were analyzed by Tukey’s studentized range test for 
BPH parameters. BPH parameters for IPSS, QoL, serum PSA, 
PV and MFR were expressed as the mean ± standard error, and 
were age adjusted against group A (control), in which acquired 
by analysis of covariance (ANCOVA) with least square mean 
(LSMEAN). Also Pearson correlation was compared between 
parameters. SAS 9.01 (SAS Institute Inc., Cary, NC, USA) was 
used for statistical analysis.
Results 
General characteristics for the patients are shown in Table 1. 
The average age of patients who completed the 1 year trial was 
53.3 years, and the average age of group D was significantly 
higher than those of groups B and C (Table 1). The average 
height, weight and BMI of patients were not significantly 
different among groups, and the average BMIs of all groups were 
within an overweight range based on Korean obesity evaluation 
criteria (Lee et al., 2006). 
IPSSs in groups B, C and D were significantly reduced (P
< 0.05) after 3 months of treatment (Table 2). IPSS of group 
B was decreased by 12.0 points (58.0% change), from 20.7 to 
8.7 after 12-month treatment. IPSS of group C was also decreased Heeok Hong et al. 325
Table 3. Quality of life scores 
Group Baseline 3 Months 6 Months 9 Months 12 Months
A (n=7) 3.2 ± 0.4
1) 2.7 ± 0.4
(-15.8%)
2.8 ± 0.5
(-12.5%)
2.9 ± 0.5
(-9.4%)
2.8 ± 0.5
(-12.5%)
B (n=16) 4.2 ± 0.4
a 3.0 ± 0.4
b
(-28.6%)
 3.4 ± 0.4
bc
(-19.0%)
 2.8 ± 0.4
bc
(-33.3%)
2.5 ± 0.4
c
(-40.5%)
C (n=13) 3.6 ± 0.3
a 3.0 ± 0.4
b
(-16.7%)
2.5 ± 0.4
b
(-30.6%)
 2.2 ± 0.4
b
(-38.9 %)
2.2 ± 0.4
b
(-38.9%)
D (n=11) 3.8 ± 0.4
a 4.3 ± 0.5
ab
(13.2%)
 2.5 ± 0.5
bc
(-34.2%)
2.0 ± 0.5
c
(-47.4%)
1.6 ± 0.4
c
(-57.9%)
1) Mean ± SE  (adjusted  for  age)
Different superscripts within the same row are significantly different at α=0.05 by 
Tukey’s  range  test  with  age  adjusted.
Table 4. Serum prostate specific antigen (ng/ml) 
Group Baseline 3 Months 6 Months 9 Months 12 Months
A (n=7) 1.0 ± 0.3
1) 0.7 ± 0.3
(-30.0%)
0.9 ± 0.3
(-10.0%)
1.2 ± 0.2
(20.0%)
1.1 ± 0.3
(10.0%)
B (n=16) 0.8 ± 0.4 0.5 ± 0.2 
(-37.5%)
0.5 ± 0.2
(-37.5%)
0.7 ± 0.2
 
(-12.5%)
0.9 ± 0.3
 
(10.0%)
C (n=13) 1.2 ± 0.2
  1.0 ± 0.2
 
(-16.7%)
1.1 ± 0.2
(-8.3%)
1.1 ± 0.2
 
(-8.3%)
1.1 ± 0.2
 
(-8.3%)
D (n=11) 1.2 ± 0.3
a 0.5 ± 0.2
b
(-58.3%)
0.4 ± 0.3
b
(-66.7%)
0.6 ± 0.2
b
(-50.0%)
0.7 ± 0.3
b
(-41.7%)
1) Mean ± SE  (adjusted  for  age)
Different superscripts within the same row are significantly different at α=0.05 by 
Tukey’s  range  test  with  age  adjusted.
Table 5. Prostate volume (ml)
Group Baseline 6 Months 9 Months 12 Months
A (n=7) 23.2 ± 2.3
1) 21.2 ± 2.8
(-8.6%)
24.6 ± 2.9
(6.0%)
23.4 ± 2.3
(0.9%)
B (n=16) 22.4 ± 2.0 22.1 ± 2.4
 
(-1.3%)
21.7 ± 2.4
(-3.1%)
19.1 ± 2.0
(-14.7%)
C (n=13) 26.1 ± 1.7 27.3 ± 2.0
 
(4.6%)
27.3 ± 2.1
(4.6%)
24.8 ± 1.7
(-5.0%)
D (n=11) 25.1 ± 2.3 21.8 ± 2.8
(-13.1%)
24.7 ± 2.8
(-1.6%)
23.0 ± 2.3
(-8.4%)
1) Mean ± SE  (adjusted  for  age)
Table 6. Maximal urinary flow rate (ml/second)
Group Baseline 6 Months 9 Months 12 Months
A (n=7) 19.0 ± 2.6
1) 22.6 ± 3.2
(18.9%)
15.9 ± 3.3
(-16.3%)
14.8 ± 3.1
(-22.1%)
B (n=16) 14.8 ± 2.1
a 16.9 ± 2.6
b
(14.2%)
16.7 ± 2.7
b
(12.8%)
17.0 ± 2.5
b
(14.9%)
C (n=13) 14.0 ± 1.8
a 18.1 ± 2.3
ab
(29.3%)
17.7 ± 2.3
ab
(26.4%)
21.2 ± 2.1
b
(51.4%)
D (n=11) 20.1 ± 2.6 24.5 ± 3.3
(21.9%)
24.3 ± 3.3
(20.9%)
21.2 ± 3.1
(5.5%)
1) Mean ± SE  (adjusted  for  age)
Different superscripts within the same row are significantly different at α=0.05 by 
Tukey’s  range  test  with  age  adjusted.
by 9.2 points (50.3% change), from 18.2 to 9.1. The average 
IPSS of group D showed a constant decline from the beginning 
(19.0) to the end of the 12-month treatment (4.7) by 14.3 points, 
indicating 75.3% improvement in voiding symptoms. In 
particular, BPH status of group D was improved from moderate 
(8~19) to mild (≤7) according to IPSS. The reduction of IPSS 
after 12 month treatment was highest in group D, however, there 
was no significant difference among the groups. 
The QoL were significantly improved in groups B and C after 
3 months, and in group D after 6 months (P < 0.05) (Table 3). 
The QoL score of group A (placebo) was not changed, but those 
of group B and group C were reduced by 1.7 points (40.5% 
change) and 1.4 points (38.9% change) after 12-month treatment, 
respectively. The QoL score of group D was reduced by 2.2 
points (57.9% change) after 12-month treatment. 
Serum PSA levels are shown in Table 4. The serum PSA levels 
of groups A, B and C remained unchanged during the 12 month 
trial. The serum PSA levels of group D showed a constant decline 
from the beginning (1.2 ng/ml) to the end of the 12-month 
treatment (0.7 ng/ml), indicating 41.7 % reduction.
The PV of groups B, C and D showed a gradual decline over 
the experimental period, but these changes were not statistically 
significant (Table 5). The PV of group A remained unchanged 
over the experimental period. 
As shown in Table 6, the MFR of group A was gradually 
decreased over the experimental period with a worsening in 
urinary symptoms. The MFR of group B was significantly 
increased after 6 months and that of group C was significantly 
increased at 12 months (P < 0.05). The MFR of group B was 
increased from 14.8 ml/second at the initiation of the study to 
17.0 ml/second at the end, for an improvement of 14.9%. The 
MFR of group C was increased from 14.0 to 21.2 ml/second 
after 12-month treatment, which was an improvement of 51.4%. 
The MFR score of group D, however, was not changed 
significantly during the treatment period.
Correlation between parameters existed; IPSS vs QoL (Correla-
tion coefficient = 0.635, P < 0.05), IPSS vs MFR (Correlation 
coefficient = -0.375, P< 0.05), QoL vs MFR (Correlation coeffi-
cient = -0.255,  P < 0.05), and prostate volume vs serum PSA 
(Correlation coefficient = 0.323, P <0 . 0 5 ) .
In the meanwhile, there were no statistically significant 
differences in all BPH parameters among groups at every 
treatment time. 
Discussion
The use of phytochemicals (phytosterols) as an alternative 
therapy for the relief of lower urinary tract symptoms due to 
a prostatic disease seems to be growing quickly all over the 
world, including the Republic of Korea (Buck, 2004). A 
phytochemical based therapy is widely given to men with 
symptomatic BPH in Western Europe, where physicians prescribe 
phytochemical products in the same manner as they prescribe 
drugs (Marks et al., 2000).
The results of this study show that the symptoms of BPH for 
all patients receiving treatment with pumpkin seed oil, saw 
palmetto oil, or a combination of pumpkin seed oil plus saw 
palmetto oil were improved over 12 months, in comparison with 326 Alternative medicine treatments for BPH
placebo. But therapeutic efficiency was not improved by 
combination of these two compounds. During the experimental 
period, no side effects were reported; this was in contrast with 
Singh  et al. (2007) in similar trials. 
According to Braeckman’s study (1994), oral doses of saw 
palmetto oil 160 mg twice daily for 3 months improved IPSS 
about 22% after 45 days and 35% at 90 days. This was 
comparable with our result in which group B (33.8%) and group 
C (33.2%) showed similar improvement after 3 months. In the 
study by Bach (2000), 12-month pumpkin seed treatment 
improved the IPSS at least 5 points and overall improvement 
of 64.8%. In a double-blind randomized trial that compared the 
effects of saw palmetto (320 mg/day) with 5-α-reductase inhibitor 
(5 mg/day), the IPSS was declined by 37% and 39%, respectively 
(Carraro  et al., 1996) after 6 months of treatment. Hisashi et 
al. (2005) reported a significant linear relationship between IPSS 
and QoL score, a finding in agreement with our own, in which 
IPSS was correlated exactly with QoL score. Both IPSS and QoL 
score tended to decline significantly at the 3rd month of treatment 
in our study, a finding similar to that of other researchers (Nickel, 
1998; Willetts et al., 2003).
There have been recent reports suggesting that the serum PSA 
value may not be the best marker for prostate cancer detection, 
but it still remains one of the simplest means of early diagnosis 
and follow-ups for this disease. Serum PSA is also increased 
in other conditions such as BPH, prostatitis and others (Lee et 
al., 2005; Mehrabi et al., 2005). Debruyne et al. (2002) showed 
saw palmetto does not affect serum PSA level within 12 months 
of treatment. In our study, only a minimal change of PSA was 
observed within the normal range (0.0~4.0 ng/ml), although a 
synergistic combination of pumpkin seed oil and saw palmetto 
oil may have contributed to the decrease of serum PSA level 
observed in our study. 
Braeckman (1994) showed that prostate volume was signifi-
cantly decreased by 9% after 45 days and 10% after 90 days 
of treatment
  with saw palmetto oil. But several of reports 
demonstrated only a minimal change of prostate volume within 
1 year (Marks et al., 2000; Wilt et al., 1998). We also could 
not detect any significant decrease of the prostate volume even 
within 12 months. 
In a randomized trial of natural products by Preuss et al. 
(2001), the IPSS was decreased significantly after 90 days, but 
serum PSA, MFR and PV were not changed. This is in contrast 
to the present study in which the serum PSA of patients fed 
the combination of pumpkin seed oil and saw palmetto oil was 
decreased, and MFR in the pumpkin seed oil group was 
increased, significantly after 6 months.
In a study by Moon et al. (1990), urinary flow rate of BPH 
patients supplemented with Sitosterol was increased from a 
baseline MFR of 9.3 ml/s to 12.2 ml/s after 4 weeks of treatment, 
and continued to increase consistently for 12 weeks. Kondas et 
al. (1996) reported that the average MFR was increased from 
10.36 ml/s to 14.44 ml/s without any adverse effects after 12 
months of treatment with saw palmetto oil
  . In addition, this 
treatment did not influence the effectiveness of drugs taken for 
other chronic diseases by these patients. Carbin et al. (1990) 
studied the combination of saw palmetto with pumpkin seed oil 
and reported a significant increase in MFR value in BPH patients 
after 3 months of treatment. Our study showed a similar 
effectiveness on MFR in the pumpkin seed oil group and the 
saw palmetto oil group, but the combination of pumpkin seed 
oil with saw palmetto oil group did not significantly affect MFR.
The action mechanism of pumpkin seed oil is well known by 
its inhibition on 5-α-reductase which converts testosterone into 
DHT (dihydrotestosterone) (Gossell-Williams et al., 2006; Tsai 
et al., 2006). Meanwhile various action mechanisms are 
suggested for saw palmetto oil, including nuclear estrogen 
receptor inhibitor (Di Silverio et al., 1992), inhibition of cyclo-
oxygenase and 5-lipoxygenase pathway (Breu et al., 1992) as 
well as 5-α-reductase inhibition (Weisser et al., 1996). Recently, 
epithelial contraction in the prostate transition zone was 
demonstrated by Marks et al. (2000). According to the difference 
in action mechanisms, a synergistic effect on BPH was expected 
from combination treatment of pumpkin seed oil and saw 
palmetto oil. In our study, combination treatment of pumpkin 
seed oil and saw palmetto oil induced a higher symptomatic 
improvement, though not statistically significant, in IPSS, QoL 
and PSA than a single treatment. A better result is expected by 
increasing subject numbers and longer observation period as well 
as  in vitro mechanism studies. 
Based on the results of this study, it could be suggested that 
pumpkin seed oil and saw palmetto oil are clinically safe and 
may be effective complementary and alternative medicine for 
BPH.
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